Silo Pharma granted patent for intranasal treatment targeting PTSD, with promising approach for FDA approval.

From GlobeNewswire: 2025-02-26 13:30:00

Silo Pharma, Inc. announced the issuance of a new patent by the USPTO for their pharmacological prophylactics against stress-induced affective disorders in females. The patent, with projected number 12,239,614, supports Silo’s lead asset, SPC-15, targeting PTSD. This patent expands coverage for SPC-15 and reinforces Silo’s collaboration with Columbia University for research. SPC-15 is an intranasal treatment for stress-induced psychiatric disorders, offering a promising approach for FDA approval. Silo Pharma focuses on developing treatments for underserved conditions like PTSD, chronic pain, and CNS diseases, with innovative programs in the pipeline.

For more information, contact Silo Pharma at 800-705-0120 or [email protected].



Read more at GlobeNewswire: Silo Pharma Granted U.S. Patent for Novel Intranasal